Developments Advent nabs rare pediatric disease designation for bronchopulmonary dysplasia in preemies Advent Therapeutics received FDA rare pediatric disease designation for its vitamin A metabolic and reparative respiratory drugs for the prevention of bronchopulmonary dysplasia (BPD) in premature infants. BPD is a rare... July 20, 2023